Dolutegravir Switch Maintains Second-Line HIV Suppression

(MedPage Today) -- Switching people living with HIV from a ritonavir-boosted protease inhibitor (PI) to a dolutegravir (Tivicay)-based regimen maintained viral suppression just as well, according to a randomized trial out of Kenya. Among a cohort...
Source: MedPage Today Infectious Disease - Category: Infectious Diseases Source Type: news